Incidence, risk factors, and outcomes of central venous catheter-related thromboembolism in breast cancer patients: the CAVECCAS study

Cancer Medicine

Volumn 6, Issue 11, 2017, Pages 2732-2744

  Debourdeau, Philippe ^a   Espié, Marc ^b,c   Chevret, Sylvie ^b,c   Gligorov, Joseph ^d,e   Elias, Antoine ^f   Dupré, Pierre François ^g   Desseaux, Kristell ^b,c   Kalidi, Issa ^b   Villiers, Stephane ^b   Giachetti, Sylvie ^b,c   Frere, Corinne ^d,e,h   Farge, Dominique ^b,c  

^a Sainte Catherine Institute   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f Sainte Musse Hospital   (France)

^g BREST UNIVERSITY HOSPITAL   (France)

^h ICAN   (France)

Author keywords

Breast cancer; central venous catheter; chemotherapy; risk factors; venous thromboembolism

Indexed keywords

ANTHRACYCLINE; D DIMER; TAXANE DERIVATIVE; THROMBIN; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D;

ADJUVANT CHEMOTHERAPY; ADULT; AGE; ARTICLE; BODY MASS; BREAST CANCER; CASE CONTROL STUDY; CATHETER THROMBOSIS; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DOPPLER FLOWMETRY; FEMALE; HUMAN; LOBULAR CARCINOMA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; NEOADJUVANT CHEMOTHERAPY; PLATELET MICROPARTICLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOPHILIA; ADVERSE DEVICE EFFECT; ASYMPTOMATIC DISEASE; BIOSYNTHESIS; BREAST TUMOR; CENTRAL VENOUS CATHETER; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DOPPLER ULTRASONOGRAPHY; DOUBLE BLIND PROCEDURE; INCIDENCE; MEMBRANE MICROPARTICLE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PAGET NIPPLE DISEASE; PATHOLOGY; RISK FACTOR; THROMBOCYTE; THROMBOEMBOLISM;

AGE FACTORS; ASYMPTOMATIC DISEASES; BLOOD PLATELETS; BODY MASS INDEX; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CASE-CONTROL STUDIES; CELL-DERIVED MICROPARTICLES; CENTRAL VENOUS CATHETERS; COMORBIDITY; DOUBLE-BLIND METHOD; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; THROMBIN; THROMBOEMBOLISM; THROMBOPHILIA; ULTRASONOGRAPHY, DOPPLER;

EID: 85032926311     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.1201     Document Type: Article

References (44)

1. Breast Cancer Statistics | World Cancer Research Fund International. Published November 18, 2016. Available at http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/breast-cancer-statistics (accessed 18 November 2016).
2. Cronin-Fenton, D. P., F. Søndergaard, L. A. Pedersen, J. P. Fryzek, K. Cetin, J. Acquavella, et al. 2010. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997–2006. Br. J. Cancer 103:947–953.
3. Walker, A. J., T. R. Card, J. West, C. Crooks, and M. J. Grainge. 2013. Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases. Eur. J. Cancer Oxf. Engl. 49:1404–1413.
4. Timp, J. F., S. K. Braekkan, H. H. Versteeg, and S. C. Cannegieter. 2013. Epidemiology of cancer-associated venous thrombosis. Blood 122:1712–1723.
5. Brand, J. S., E. Hedayati, N. Bhoo-Pathy, et al. 2016. Time-dependent risk and predictors of venous thromboembolism in breast cancer patients: a population-based cohort study. Cancer 123:468–475.
6. Walker, A. J., J. West, T. R. Card, C. Crooks, C. C. Kirwan, and M. J. Grainge. 2016. When are breast cancer patients at highest risk of venous thromboembolism? A cohort study using English health care data. Blood 127:849–857; quiz 953.
7. Amir, E., B. Seruga, S. Niraula, L. Carlsson, and A. Ocaña. 2011. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J. Natl. Cancer Inst. 103:1299–1309.
8. Paulus, J. K., and A. S. Rosenberg. 2016. Breast cancer and thrombosis: timing matters. Blood 127:793–794.
9. Verso, M., and G. Agnelli. 2003. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J. Clin. Oncol. 21:3665–3675.
10. Lee, A. Y. Y., and P. W. Kamphuisen. 2012. Epidemiology and prevention of catheter-related thrombosis in patients with cancer. J. Thromb. Haemost. 10:1491–1499.
11. McGee, D. C., and M. K. Gould. 2003. Preventing complications of central venous catheterization. N. Engl. J. Med. 348:1123–1133.
12. Farge, D., H. Bounameaux, B. Brenner, et al. 2016. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 17:e452–e466.
13. Schiffer, C. A., P. B. Mangu, J. C. Wade, et al. 2013. Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 31:1357–1370.
14. Debourdeau, P., D. Farge, M. Beckers, et al. 2013. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J. Thromb. Haemost. 11:71–80.
15. Debourdeau, P., D. Kassab Chahmi, G. Le Gal, et al. 2009. 2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group. Ann. Oncol. 20:1459–1471.
16. Saber, W., T. Moua, E. C. Williams, et al. 2011. Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies. J. Thromb. Haemost. 9:312–319.
17. van Rooden, C. J., F. R. Rosendaal, R. M. Y. Barge, et al. 2003. Central venous catheter related thrombosis in haematology patients and prediction of risk by screening with Doppler-ultrasound. Br. J. Haematol. 123:507–512.
18. Robert, S., P. Poncelet, R. Lacroix, et al. 2009. Standardization of platelet-derived microparticle counting using calibrated beads and a Cytomics FC500 routine flow cytometer: a first step towards multicenter studies? J. Thromb. Haemost. 7:190–197.
19. Ridker, P. M., C. H. Hennekens, K. Lindpaintner, M. J. Stampfer, P. R. Eisenberg, and J. P. Miletich. 1995. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N. Engl. J. Med. 332:912–917.
20. Poort, S. R., F. R. Rosendaal, P. H. Reitsma, and R. M. Bertina. 1996. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88:3698–3703.
21. Ay, C., D. Dunkler, R. Simanek, et al. 2011. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna cancer and thrombosis study. J. Clin. Oncol. 29:2099–2103.
22. Horsted, F., J. West, and M. J. Grainge. 2012. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med. 9:e1001275.
23. Joffe, H. V., N. Kucher, V. F. Tapson, and S. Z. Goldhaber. 2004. Deep vein thrombosis (DVT) FREE Steering Committee. Upper-extremity deep vein thrombosis: a prospective registry of 592 patients. Circulation 110:1605–1611.
24. Kuter, D. J. 2004. Thrombotic complications of central venous catheters in cancer patients. Oncologist 9:207–216.
25. Morazin, F., I. Kriegel, B. Asselain, and M. C. Falcou. 2005. [Symptomatic thrombosis in central venous catheter in oncology: a predictive score?]. Rev. Med Interne. 26:273–279.
26. Lee, A. Y. Y., M. N. Levine, G. Butler, et al. 2006. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J. Clin. Oncol. 24:1404–1408.
27. Monreal, M., A. Raventos, R. Lerma, et al. 1994. Pulmonary embolism in patients with upper extremity DVT associated to venous central lines–a prospective study. Thromb. Haemost. 72:548–550.
28. Ge, X., R. Cavallazzi, C. Li, S. M. Pan, Y. W. Wang, and F.-L. Wang. 2012. Central venous access sites for the prevention of venous thrombosis, stenosis and infection. Cochrane Database Syst. Rev. 14:CD004084.
29. Khorana, A. A., N. M. Kuderer, E. Culakova, G. H. Lyman, and C. W. Francis. 2008. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111:4902–4907.
30. Lips, E. H., R. A. Mukhtar, C. Yau, et al. 2012. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. Breast Cancer Res. Treat. 136:35–43.
31. Chen, C.-L., N. S. Weiss, P. Newcomb, W. Barlow, and E. White. 2002. Hormone replacement therapy in relation to breast cancer. JAMA 287:734–741.
32. Inoue, M., H. Nakagomi, H. Nakada, et al. 2017. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer. Breast Cancer 24:667–672.
33. Rosendaal, F. R., F. M. Helmerhorst, and J. P. Vandenbroucke. 2002. Female hormones and thrombosis. Arterioscler. Thromb. Vasc. Biol. 22:201–210.
34. Jansen, F. H., H. M. van der Straaten, M. Roest, F. Haas, P. G. de Groot, and R. Fijnheer. 2005. Elevated levels of D-dimer and fragment 1+2 upon central venous catheter insertion and factor V Leiden predict subclavian vein thrombosis. Haematologica 90:499–504.
35. Kanno, Y., K. Kobayashi, H. Takane, et al. 2007. Elevation of plasma D-dimer is closely associated with venous thrombosis produced by double-lumen catheter in pre-dialysis patients. Nephrol. Dial. Transplant. 22:1224–1227.
36. Geddings, J. E., and N. Mackman. 2013. Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood 122:1873–1880.
37. Wermes, C., M. von Depka Prondzinski, R. Lichtinghagen, M. Barthels, K. Welte, and K. W. Sykora. 1999. Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters. Eur. J. Pediatr. 158(Suppl. 3):S143–S146.
38. Fijnheer, R., B. Paijmans, L. F. Verdonck, H. K. Nieuwenhuis, M. Roest, and A. W. Dekker. 2002. Factor V Leiden in central venous catheter-associated thrombosis. Br. J. Haematol. 118:267–270.
39. Van Rooden, C. J., F. R. Rosendaal, A. E. Meinders, J. A. Van Oostayen, F. J. M. Van Der Meer, and M. V. Huisman. 2004. The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis. Haematologica 89:201–206.
40. Mandalà, M., G. Curigliano, P. Bucciarelli, et al. 2004. Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. Ann. Oncol. 15:590–593.
41. Lyman, G. H., K. Bohlke, A. A. Khorana, et al. 2015. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014. J. Clin. Oncol. 33:654–656.
42. Young, A. M., L. J. Billingham, G. Begum, et al. 2009. Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet Lond. Engl. 373:567–574.
43. De Cicco, M., M. Matovic, L. Balestreri, et al. 2009. Early and short-term acenocumarine or dalteparin for the prevention of central vein catheter-related thrombosis in cancer patients: a randomized controlled study based on serial venographies. Ann. Oncol. 20:1936–1942.
44. D'Ambrosio, L., M. Aglietta, and G. Grignani. 2014. Anticoagulation for central venous catheters in patients with cancer. N. Engl. J. Med. 371:1362–1363.